BDSX Biodesix

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a . The Top Workplaces program has an 18-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. This recognition is based solely on gathered through a third-party survey, administered by employee engagement technology partner, .

The confidential survey uniquely measures the employee experience and its component themes, including employees feeling respected & supported, enabled to grow, and empowered to execute, to name just a few key attributes of a top-performing workplace.

“I want to first recognize each of the Biodesix team members for their direct contributions in cultivating our high performing and fulfilling workplace culture,” said Scott Hutton, CEO & President of Biodesix, Inc. “As one of only 150 companies to earn this recognition, it reinforces that Biodesix is an employer of choice and reflects our team’s enthusiasm to continue building our unique culture. Thank you again to the team for their commitment to excellence in serving our healthcare customers, their patients, and our industry partners as we continue driving towards the Biodesix mission and vision.”

This is the company’s second consecutive year being recognized as a great place to work through comprehensive anonymous employee surveys on critical themes measuring employee engagement and workplace culture. Last year, Biodesix received the prestigious award.

“In today's market, leaders must ensure they’re cultivating a workplace where employees have a voice, and they are heard. Earning a Top Workplaces award is an exclusive badge of honor for companies, especially because it comes authentically from their employees,” said Eric Rubino, Energage CEO. “That's something to be very proud of.”

ABOUT BIODESIX

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences tools and diagnostics companies, and academic research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information on our culture and operating principles (Team, Impact, Excellence), please see our website:

ABOUT ENERGAGE

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 18 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. For more information, visit or .

Contacts:

Media:

Natalie St. Denis, Director Corporate Communications, Biodesix



+1 (720) 925-9285

Investors:

Chris Brinzey, Partner, Westwicke Group



+1 (339) 970-2843



EN
14/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

 PRESS RELEASE

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a . The Top Workplaces program has an 18-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. This recognition is based solely on gathered through a third-party survey, administered by employee engagement technology partner, . The confidential survey uniquely measures the employee experience and its component themes, includi...

 PRESS RELEASE

Biodesix Announces First Quarter 2025 Results and Highlights

Biodesix Announces First Quarter 2025 Results and Highlights Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025. “Our quarter was highlighted by continued progres...

 PRESS RELEASE

Biodesix to Report First Quarter 2025 Financial Results on May 13, 202...

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this . Analysts who wish to participate in the qu...

 PRESS RELEASE

Biodesix partner, Friends of Cancer Research, publishes data in Clinic...

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology LOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (Nasdaq: BDSX), a leading diagnostics solutions company, and Bio-Rad Laboratories (NYSE: BIO), a global leader in life sc...

 PRESS RELEASE

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., March 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). "Biodesix concluded a strong 2024, advancing our key initiatives an...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch